Corporate Announcements

Screen Shot 2013-06-07 at 9.34.31 AM

November, 2015
ISN – iSonea Appoints Deloitte Touche Tohmatsu as Company Auditor – 30 November, 2015

ISN – 2015 Annual General Meeting – Chairman’s Address – 26 November, 2015

ISN – Results of iSonea 2015 Annual General Meeting – 26 November, 2015

ISN – Chicago University IRB Approves AirSonea Research Study – 25 November, 2015

ISN – iSonea to Exhibit at China Hi-Tech Fair in Shenzhen China – 5 November, 2015

October, 2015
ISN – Notice of Annual General Meeting & Explanatory Memorandum – 23 October, 2015

ISN – Appendix 4C – quarterly – 26 October, 2015

August, 2015
ISN – Appendix 4E Preliminary Final Report – 31 August, 2015

ISN – Change of Registered Office – 20 August, 2015

ISN – Clinical Trial Update – Second Generation AirSonea – 12 August, 2015

ISN – Major Advance for Second Generation AirSonea® Wheeze Monitor – 6 August, 2015

July, 2015
ISN – Appendix 4C – Fourth Quarter Cash Report – FY2015 – 23 July, 2015

ISN – iSonea Presents at Canary Biotech & Healthcare Investor Show – 08 July, 2015

June, 2015
ISN – iSonea to Commence Commercial Partnership Discussions – 03 June, 2015

May, 2015
ISN Update – Nth American Mkt & Clinical Trials – 28 May, 2015

April, 2015
Appendix 4C – Third Quarter Cash Report – 28 April 2015

March, 2015
Appendix 3Y – Change in Directors Interest Notice (RBH) – 20 March 2015

Appendix 3Y – Change in Directors Interest Notice (JR) – 5 March 2015

Appendix 3Y – Change in Directors Interest Notice (TCO) – 12th December 2014

Appendix 3Y – Change in Directors Interest Notice (JR) – 5 March 2015

Appendix 3Y – Change in Directors Interest Notice (LL) – 4 March 2015

January, 2015
Appendix 4D Half Yearly Report – 27 February 2015

iSonea Company Update – 27 February 2015

Appendix 4C – 2nd Quarter

iSonea’s Technology Platform Strengthened in Preparation for Clinical Trial and Product Relaunch

December, 2014
iSonea Appendix 3B and Cleansing Notice 12 December 2014

September, 2014
iSonea Accelerating Commercialisation After Strengthening Business Platform

August, 2014
iSonea Strengthens its Leadership in Respiratory Mobile Health Technology

June, 2014
Quarterly Activities Report: June 2014

 

April, 2014
Quarterly Activities Report: March 2014

 

February, 2014

Appendix 3B – Quotation of Additional Securities and Agreement

iSonea Takes Next Steps to Commercialise Asthma Management Technology

 

January, 2014

iSonea’s Asthma Technology Awarded at International CES Conference

Appendix 3B – Application for Quotation of Additional Securities and Agreement

Appendix 3X – Initial Director’s Interest Notice 

Appendix 3Z – Final Director’s Interest Notice

iSonea Announces Board of Director and Management Changes 
December, 2013

iSonea To Drive Aggressive AirSonea™ Sales Plan in Australia

Change of Director’s Interests, Washer

New Issue Announcement, Application for Quotation of Additional Securities and Agreement

 

November, 2013

New Issue Announcement, Application for Quotation of Additional Securities and Agreement

iSonea Technology Featured on National Television Program

iSonea CEO to Step Down

 

 

October, 2013

iSonea releases Q1 Report

Annual General Meeting Report

Procter & Gamble’s TREMOR™ to Promote AirSonea™ to Women

iSonea CEO to Present at Australian Biotech Investment Conference

Application for Additional Securities and Agreement

iSonea Chairman to Present at Prestigious Australian Medical Conference

iSonea Partners with uHealth to Distribute AirSonea Technology via Pharmacies

iSonea CEO to Present at Prestigious International Mobile Health Conference

Application for Additional Securities and Agreement

Notice of Annual General Meeting and Explanatory Memorandum

iSonea releases Annual Report for 2013

Application for Additional Securities and Agreement

 

September, 2013

iSonea Launches Mobile Health Technology AirSonea™

Application for Additional Securities

iSonea Achieves CE Mark for AirSonea™

Appendix 3B: Announcement for application for quotation of additional securities

 

August, 2013

iSonea Releases Preliminary Annual Report

iSonea Receives Prestigious Innovation Award

Appendix 3B: Announcement for application for quotation of additional securities

ISN ASX Confirm AirSonea TGA Listing

iSonea Achieves Therapeutic Goods Administration Listing for AirSonea

 

July, 2013

Recently Released: Quarterly Report – June 2013

Appendix 3B: Exercise of Options

New Issue Announcement for Quotation of Additional Securities and Agreement

Investor Presentation: July 2013

iSonea Completes $13.5M Private Placement

Notice of Change of Interests of Substantial Holder

 

June, 2013

iSonea Raises $13.5 million via Private Placement

iSonea Selects International Manufacturing Partner to Scale Up
AirSonea™ Production

Physicians Overwhelmingly Support AirSonea™

 

May, 2013

Appendix 3B – New Issue Announcement

 

April, 2013

Quarterly Activities Report – 31 March 2013

iSonea CEO to Present at Investor Forum

New Issue of iSonea Newsletter Available

New Investor Presentation

New issue announcement, application for quotation of additional securities and agreement

Change of Director’s Interest Notice

iSonea Launches New Asthmasense™ Cloud Technology

 

March, 2013

iSonea to Unveil New Asthma Technology at Australian Asthma Conference

iSonea Unveils Regulatory Plans for AirSonea™ Wheeze Monitor

 

February, 2013

iSonea Half Year Report

Dr. Stewart Washer Presentation to BioMelbourne Mobile Health Conference

Change of Director’s Interest Notice

 

January, 2013

iSonea Chairman to Present at BioMelbourne Mobile Health Conference

Second Quarterly Report

iSonea Limited Announces Free Issuance Period for Conversion of KMLXF Shares to ISOAY ADRs

 

December, 2012

iSonea Previews AsthmaSense v1.1 at mHealth Summit

 

November, 2012

Results of Annual General Meeting

Change of Director’s Interest Notice: Washer

Change of Director’s Interest Notice: Dantzker

Change of Director’s Interest Notice: Korten

Change of Director’s Interest Notice: Haghighat

Change of Director’s Interest Notice: MacDonald

 

October, 2012

iSonea Q1 Report 2013

ISN ASX Confirm Rights Issue Shortfall

Notice of Annual General Meeting and Explanatory Memorandum

Dispatch of Renounceable Pro-Rate Rights Issue Prospectus

iSonea Files FDA Submission for Over-the-Counter SonoSentry™

 

September, 2012

2012 Annual Report

Letter to Eligible Shareholders on Rights Issue

Letter to Ineligible Shareholders on Rights Issue

iSonea Announces Fully Underwritten Renounceable Rights Issue to Raise $4M

Appendix 3B: application for quotation of additional securities and agreement

Prospectus: Offer to Eligible Shareholders

Letter to Option Holders

iSonea App Now Free

 

August, 2012

Preliminary Final Report

Notice of Initial Substantial Holder

Bruce Mathieson Becomes Cornerstone Investor of iSonea

Application for Quotation of Additional Securities and Agreement

Change of Director’s Interest Notice, Washer

Change of Director’s Interest Notice, Haghighat

Change of Director’s Interest Notice, Dantzker

Change of Director’s Interest Notice, Korten

Change of Director’s Interest Notice, Washer

iSonea Completes Capital Consolidation

Isonea run successful App trial in Memphis

iSonea Launches Updated AsthmaSense™ Smartphone App for Global Market

Change of Director’s Interest Notice

iSonea Fourth Quarter Results

iSonea Trading Policy

 

July, 2012

iSonea Announces Results of General Meeting

General Meeting Presentation by Micheal Thomas: Value Appreciation Via Sound Asthma Management

iSonea Announces New Chairman of the Board

 

June, 2012

Updated Capital Consolidation Timetable

Letter to Shareholders

Sharholder Meeting

OzEquities Analyst Report: Isonea Has Market Leading Asthma Monitoring Products …

iSonea Launches First Mobile Asthma Technology

 

Archived ASX, Investor and Corporate Announcements

 

Contact Info

For Business Inquiries:

iSonea Ltd
Registered Office
Level 29, South Tower
525 Collins Street
Melbourne VIC 3000
Ph: +61 (0) 3 9824 5254
info@iSonea.com

Israel
16 Pal-Yam Avenue
Haifa 3309523 Israel
Ph: 972-4-861-5025
Fax: 972-4-866-7702

2-1.2advamed

FrostandSullivan_Logo